
Sign up to save your podcasts
Or
Big tech taking the lead, and driving the S&P 500 and Nasdaq to fresh record highs. How semis, software, and other sections of the tech trade can fuel your portfolio. Plus Fast Money’s Obesity Week coverage continues. Eli Lilly’s Chief Scientific Officer breaks down how the company’s obesity drug Zepbound performed in its first head-to-head clinical trial against Novo’s Wegovy, and what the results could mean for the weight loss drug wars.
Fast Money Disclaimer
3.9
12251,225 ratings
Big tech taking the lead, and driving the S&P 500 and Nasdaq to fresh record highs. How semis, software, and other sections of the tech trade can fuel your portfolio. Plus Fast Money’s Obesity Week coverage continues. Eli Lilly’s Chief Scientific Officer breaks down how the company’s obesity drug Zepbound performed in its first head-to-head clinical trial against Novo’s Wegovy, and what the results could mean for the weight loss drug wars.
Fast Money Disclaimer
4,132 Listeners
241 Listeners
3,201 Listeners
148 Listeners
344 Listeners
68 Listeners
154 Listeners
2,126 Listeners
2,033 Listeners
616 Listeners
557 Listeners
20 Listeners
189 Listeners
411 Listeners
303 Listeners
118 Listeners
794 Listeners
182 Listeners
60 Listeners
169 Listeners
28 Listeners
33 Listeners
11 Listeners
9 Listeners
265 Listeners
10 Listeners